Prostate cancer imaging

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue SUPPL. 1, 2013, Pages

  Picchio, Maria ^a,b   Piert, Morand ^c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; TRACER; RADIOPHARMACEUTICAL AGENT; DIAGNOSTIC AGENT;

CANCER RECURRENCE; HUMAN; IMAGE ANALYSIS; IMAGING SYSTEM; MULTIMODAL IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PROSTATE CANCER; REVIEW; DIAGNOSTIC USE; MALE; PROSTATIC NEOPLASMS; SCINTISCANNING; EDITORIAL; PROSTATE TUMOR;

HUMANS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 84888004433     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2444-5     Document Type: Review

References (24)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: Cancer J Clin. 2012;62:10-29.
2. Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostatespecific antigen progression after radical treatment of prostate cancer. Eur Urol. 2011;59:51-60.
3. 11C-Choline PET/CT and PSA kinetics. Eur J Nucl Med Mol Imaging. 2013. doi:10.1007/s00259-013- 2377-z
4. Dost RJ, Glaudemans AWJM, Breeuwsma AJ, de Jong IJ. Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2013. doi:10.1007/s00259-013-2398-7
5. Schwarzenböck SM, Kurth J, Gocke C, Kuhnt T, Hildebrandt G, Krause BJ. Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer. Eur J Nucl Med Mol Imaging. 2013. doi:10.1007/s00259-013- 2404-0
6. Picchio M, Giovannini E, Crivellaro C, Gianolli L, di Muzio N, Messa C. Clinical evidence on PET/CT for radiation therapy planning in prostate cancer. Radiother Oncol. 2010;96:347-50.
7. 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients. Eur J Nucl Med Mol Imaging. 2013. doi:10.1007/ s00259-013-2358-2
8. Jadvar H. Imaging evaluation of prostate cancer with 18Ffluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013. doi:10.1007/s00259-013-2361-7
9. 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. Eur J Nucl Med Mol Imaging. 2013. doi:10.1007/s00259-013- 2373-3
10. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [(68)Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2012;40:486-95.
11. 18F-labeled bombesin analog. J Nucl Med. 2012;53:947-52.
12. Grant K, Lindenberg ML, Shebel H, Pang Y, Agarwal HK, Bernardo M, et al. Functional and molecular imaging of localized and recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2013. doi:10.1007/s00259-013-2419-6
13. Turkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, McKinney YL, et al. Prostate cancer: value ofmultiparametricMR imaging at 3 T for detection-histopathologic correlation. Radiology. 2010;255:89-99.
14. 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging. 2005;32:742-8.
15. 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin. 2007;46:161-8. quiz N47-8.
16. Beer AJ, Eiber M, Souvatzoglou M, Holzapfel K, Ganter C, Weirich G, et al. Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in 11Ccholine PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer. Mol Imaging Biol. 2011;13:352-61.
17. Spur EM, Decelle EA, Cheng LL. Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry. Eur J Nucl Med Mol Imaging. 2013. doi:10.1007/ s00259-013-2379-x
18. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:910-4.
19. Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS, et al. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res. 2005;65:3030-4.
20. Souvatzoglou M, Eiber M, Martinez-Moeller A, Fürst S, Holzapfel K, Maurer T, et al. PET/MR in prostate cancer: technical aspects and potential diagnostic value. Eur J Nucl Med Mol Imaging. 2013. doi:10.1007/s00259-013-2445- 4
21. Vargas HA, Akin O, Shukla-Dave A, Zhang J, Zakian KL, Zheng J, et al. Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study. Radiology. 2012;265:478-87.
22. 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med. 2009;50:1585-93.
23. Park H, Wood D, Hussain H, Meyer CR, Shah RB, Johnson TD, et al. Introducing parametric fusion PET/MRI of primary prostate cancer. J Nucl Med Mol Imaging. 2012;53:546-51.
24. Meyer C, Ma B, Kunju LP, Davenport M, Piert M. Challenges in accurate registration of 3-D medical imaging and histopathology in primary prostate cancer. Eur J Nucl Med Mol Imaging. 2013. doi:10.1007/s00259-013-2382-2